📊 PDEX Key Takeaways
Is Pro Dex Inc. (PDEX) a Good Investment?
PRO DEX demonstrates strong operational fundamentals with 23.7% revenue growth, expanding margins (18.9% net, 16.6% operating), and robust free cash flow generation of $7.2M. The company maintains a conservative balance sheet (0.34x debt/equity, 3.67x current ratio) with excellent interest coverage, though sustainability concerns exist given the extreme net income spike and modest cash position relative to debt levels.
Pro Dex Inc. Key Strengths (PDEX)
- Strong revenue growth of 23.7% YoY with maintained/expanded profitability margins across gross, operating, and net levels
- Excellent balance sheet quality with conservative leverage (0.34x debt/equity), strong liquidity (3.67x current ratio, 2.14x quick ratio), and comfortable debt service (17.5x interest coverage)
- Positive free cash flow conversion with $7.2M FCF and 12.7% FCF margin, supported by capital-light business model ($280K capex)
PDEX Stock Risks: Pro Dex Inc. Investment Risks
- Extraordinary 5692% YoY net income growth compared to 23.7% revenue growth suggests prior year included substantial losses or one-time charges, raising sustainability questions on normalized profitability
- Modest cash position of $6.6M relative to $15.4M long-term debt creates limited financial cushion despite strong coverage ratios
- Small-cap company ($75M assets) in regulated medical device sector faces execution risk and potential competitive pressures without demonstrated R&D commitment or product pipeline visibility
Key Metrics to Watch
- Revenue growth sustainability and gross margin trends over next 2-3 quarters
- Operating cash flow conversion and free cash flow generation consistency
- Cash accumulation trajectory and long-term debt reduction progress
- Customer concentration risk and retention rates in medical instruments segment
Pro Dex Inc. (PDEX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.67x current ratio provides a solid financial cushion.
PDEX Profit Margin, ROE & Profitability Analysis
PDEX vs Healthcare Sector: How Pro Dex Inc. Compares
How Pro Dex Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Pro Dex Inc. Stock Overvalued? PDEX Valuation Analysis 2026
Based on fundamental analysis, Pro Dex Inc. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Pro Dex Inc. Balance Sheet: PDEX Debt, Cash & Liquidity
PDEX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Pro Dex Inc.'s revenue has grown significantly by 75% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.60 reflects profitable operations.
PDEX Revenue Growth, EPS Growth & YoY Performance
PDEX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $17.4M | $3.3M | $0.98 |
| Q2 2026 | $16.8M | $2.0M | $0.61 |
| Q1 2026 | $14.9M | $2.5M | $0.75 |
| Q3 2025 | $14.3M | $540.0K | $0.15 |
| Q2 2025 | $12.6M | -$115.0K | $-0.03 |
| Q1 2025 | $11.9M | -$615.0K | $-0.17 |
| Q3 2024 | $13.1M | $540.0K | $0.15 |
| Q2 2024 | $11.3M | -$115.0K | $-0.03 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Pro Dex Inc. Dividends, Buybacks & Capital Allocation
PDEX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Pro Dex Inc. (CIK: 0000788920)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PDEX
What is the AI rating for PDEX?
Pro Dex Inc. (PDEX) has an AI grade of A with 75% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PDEX's key strengths?
Claude: Strong revenue growth of 23.7% YoY with maintained/expanded profitability margins across gross, operating, and net levels. Excellent balance sheet quality with conservative leverage (0.34x debt/equity), strong liquidity (3.67x current ratio, 2.14x quick ratio), and comfortable debt service (17.5x interest coverage).
What are the risks of investing in PDEX?
Claude: Extraordinary 5692% YoY net income growth compared to 23.7% revenue growth suggests prior year included substantial losses or one-time charges, raising sustainability questions on normalized profitability. Modest cash position of $6.6M relative to $15.4M long-term debt creates limited financial cushion despite strong coverage ratios.
What is PDEX's revenue and growth?
Pro Dex Inc. reported revenue of $57.1M.
Does PDEX pay dividends?
Pro Dex Inc. does not currently pay dividends.
Where can I find PDEX SEC filings?
Official SEC filings for Pro Dex Inc. (CIK: 0000788920) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PDEX's EPS?
Pro Dex Inc. has a diluted EPS of $3.27.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is PDEX's fundamental grade?
Based on our AI fundamental analysis in May 2026, Pro Dex Inc. has a A grade with 75% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is PDEX stock overvalued or undervalued?
Valuation metrics for PDEX: ROE of 23.9% (sector avg: 15%), net margin of 18.9% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
What is PDEX's AI grade for 2026?
Our dual AI analysis gives Pro Dex Inc. a combined A grade for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is PDEX's free cash flow?
Pro Dex Inc.'s operating cash flow is $7.5M, with capital expenditures of $280.0K. FCF margin is 12.7%.
How does PDEX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 18.9% (avg: 12%), ROE 23.9% (avg: 15%), current ratio 3.67 (avg: 2).